{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:14:49Z","timestamp":1767147289697,"version":"build-2238731810"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T00:00:00Z","timestamp":1572652800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jtho.2018.08.2024","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T18:07:30Z","timestamp":1540404450000},"page":"1619-1622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treat it or Leave it: Immuno-Oncology in Mesothelioma Observed by the Eyes of Argus"],"prefix":"10.1016","volume":"13","author":[{"given":"Cornedine J.","family":"de Gooijer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.08.2024_bib1","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2024_bib2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant\u00a0mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.08.2024_bib3","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2024_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14737140.2017.1311791","article-title":"Pembrolizumab\u00a0for the treatment of non\u2013small cell lung\u00a0cancer","volume":"17","author":"Muller","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jtho.2018.08.2024_bib5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2024_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.08.2024_bib7","doi-asserted-by":"crossref","first-page":"S1883","DOI":"10.1016\/j.jtho.2017.09.634","article-title":"MA 19.01 A phase II study of nivolumab: a Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)","volume":"12","author":"Goto","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2024_bib8","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.329","article-title":"OA 02.02 ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma: a phase II study","volume":"12","author":"Disselhorst","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 18","key":"10.1016\/j.jtho.2018.08.2024_bib9","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase II trial","volume":"35","author":"Scherpereel","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.08.2024_bib10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.08.2024_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with\u00a0mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2018.08.2024_bib12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.08.2024_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2018.08.2024_bib14","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","article-title":"Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM)","volume":"36","author":"Desai","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2018.08.2024_bib15","doi-asserted-by":"crossref","first-page":"8514","DOI":"10.1200\/JCO.2017.35.15_suppl.8514","article-title":"Outcomes of anti\u2013PD-1 therapy in mesothelioma and correlation with PD-L1 expression","volume":"35","author":"Rivalland","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2018.08.2024_bib16","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.jtho.2018.12.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000}}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418330399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418330399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T05:55:26Z","timestamp":1572760526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418330399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1556086418330399"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2024","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treat it or Leave it: Immuno-Oncology in Mesothelioma Observed by the Eyes of Argus","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.08.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}